Overview
An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice
Status:
Completed
Completed
Trial end date:
2017-10-23
2017-10-23
Target enrollment:
0
0
Participant gender:
All
All
Summary
This observational trial will evaluate the effectiveness, the consistency of evaluation scores, quality of life, safety and tolerability of TCZ administered subcutaneously (SC) in participants with RA in daily clinical practice.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheCollaborator:
nv Roche sa
Criteria
Inclusion Criteria:- Participants naive to TCZ or who have received TCZ SC treatment within 8 weeks prior
to the enrolment visit can be included
- Participants in whom the treating physician has made the decision to commence TCZ SC
in accordance with the label and reimbursement criteria
Exclusion Criteria:
- Participants who have received TCZ >8 weeks prior to the enrolment visit
- Participants who have previously received TCZ SC
- Participants who have received treatment with any investigational agent within 4 weeks
before starting treatment with TCZ SC